Please assess the completion status of the following clinical trial:

Trial Title: Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of ankylosing spondylitis (AS) by treating rheumatologists, or a diagnosis of axial spondyloarthritis (axSpA) with a pelvis MRI with significant bone marrow edema on STIR sequences;~* Minimum of 18 years old;~* Are taking NSAIDs on a regular basis for AS or axSpA (defined as more than 20 days in the past month) and willing to withhold medication for one week; or having active symptoms that require initiation of NSAIDs;~* Concomitant anti-rheumatic drugs are allowed, if the dose has been stable for the past three months;~* Have active disease after initial washout period, defined by BASDAI \>=4/10, or back pain numerical rating scale (NRS)\>=4/10~Exclusion Criteria:~* Patients who have concurrent rheumatic diseases other than AS or axSpA;~* Patients who have oral corticosteroid in the past two weeks; patients who have acute peripheral arthritis;~* Patients with a fibromyalgia score \>= 13;~* Patient with extensive cardiac history, history of gastrointestinal bleeding that required blood transfusion, chronic kidney diseases, abnormal liver function tests; or female patients who are pregnant.~Use of low-dose of aspirin (\<100mg daily) is allowed in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indomethacin (Type: ACTIVE_COMPARATOR): Indomethacin Extended Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
- Diclofenac (Type: ACTIVE_COMPARATOR): Diclofenac Delayed Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
- Meloxicam (Type: ACTIVE_COMPARATOR): Meloxicam tablet 7.5mg by mouth, every 12 hours for 6 weeks
- Celecoxib (Type: ACTIVE_COMPARATOR): Celecoxib 200mg capsule by mouth, every 12 hours for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).